Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Prospective Study Addressing the Kinetics and Impact on Survival of Measurable Residual Disease in Acute Myeloid Leukemia Patients Receiving Azacitidine and Venetoclax

NCT06090786 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT06090786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06090786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Prospective Study Addressing the Kinetics and Impact on Survival of Measurable Residual Disease in Acute Myeloid Leukemia Patients Receiving Azacitidine and Venetoclax
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 31, 2024
Completion date
July 31, 2027
Enrollment
225 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult, minimal residual disease